Search Results - "Benerezy, K."

837TiPPRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial by Guimbaud, R, Quero, L, Vendrely, V, Tougeron, D, Benerezy, K, Samalin, E, Aparicio, T, Zitvogel, L, Selves, J, Otal, P, Cohen-Jonathan Moyal, E L, Delord, J-P, Pezzella, V, Filleron, T, Modesto, A

“…Abstract Background Overall survival (OS) of locally advanced esophageal cancer remains poor with a 5-year survival of 15-34%. The standard treatment is…”
Get full text

837TiP - PRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial by Guimbaud, R., Quero, L., Vendrely, V., Tougeron, D., Benerezy, K., Samalin, E., Aparicio, T., Zitvogel, L., Selves, J., Otal, P., Cohen-Jonathan Moyal, E.L., Delord, J.-P., Pezzella, V., Filleron, T., Modesto, A.

“…Overall survival (OS) of locally advanced esophageal cancer remains poor with a 5-year survival of 15-34%. The standard treatment is definitive radiotherapy…”
Get full text

PRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial by Guimbaud, R., Quero, L., Vendrely, V., Tougeron, D., Benerezy, K., Samalin, E., Aparicio, T., Zitvogel, L., Selves, J., Otal, P., Cohen-Jonathan Moyal, E.L., Delord, J.-P., Pezzella, V., Filleron, T., Modesto, A.

Get full text